Johnson & Johnson on Tuesday stuck with its 2007 earnings forecast despite surprisingly strong second-quarter results, sending shares down more than 1.7 percent.
Drugmaker Forest Laboratories Inc. (NYSE: FRX) posted a 34 percent rise in quarterly profit on Tuesday, beating Wall Street estimates, helped by rising sales of its Alzheimer's disease medicine.
China should not be singled out for particular concern over food safety, a big problem that rich and poor countries alike must tackle through better regulation, top World Health Organization (WHO) officials said on Tuesday.
Idenix Pharmaceuticals Inc. said on Friday it has written off its experimental hepatitis C drug after U.S. regulators ruled that the risks associated with the drug outweigh the benefits.
An experimental cancer drug from Britain's Antisoma Plc and Swiss-based Novartis AG has failed in a mid-stage clinical trial for ovarian cancer, lopping 15 percent off Antisoma's market value.
Heart risks associated with Merck & Co.'s painkiller Vioxx began much sooner than the company has claimed, The Wall Street Journal Online reported on Tuesday, citing a new study.
Austrian biotech firm Intercell won a deal to sell shares and rights to its vaccine technology to drugmaker Novartis for 270 million euros ($363 million), pushing its stock to all-time highs on Monday.
The American Medical Association said on Monday it will ask state and federal authorities to investigate retail health clinics such as those offered in CVS/Caremark stores, Wal-Mart Stores and Walgreen Co. for possible conflicts of interest.
In its heyday, Hong Kong's famous Bird Garden market bustled with shoppers bargaining in Cantonese for exotic birds for sale as pets or for Buddhist rituals.
Doctors backed away on Sunday from a controversial proposal to designate video game addiction as a mental disorder akin to alcoholism, saying psychiatrists should study the issue more.
As rising health-care costs hurt workers and retirees alike, America's trade unions are seen inching toward a broad-sweeping agreement with U.S. corporations on health-care reform.
Wall Street's push for record profits is ruining careers, tearing apart families and keeping drug dealers busy, mental health experts say.
Colgate-Palmolive Co. on Thursday said counterfeit 'Colgate' toothpaste that may contain a toxic chemical had been found in discount stores in four U.S. states.
Last week, Dr. Naresh Trehan, the top cardiologist at one of India’s largest corporate hospital groups, playing the role of a modern-day Moses, quit the research center he had led for the last 20 years, triggering an exodus of sorts, with about 50 doctors set to follow him to a rival hospital.
Advanced Medical Optics Inc. (NYSE: EYE) said it is considering an offer for Bausch & Lomb Inc. (NYSE: BOL), setting up what could become bidding war with the private equity firm Warburg Pincus LLC.
The Ministry of Economy, Trade and Industry in Japan is now requiring home appliance manufacturers to report serious accidents caused by their products, according to a report by Asashi Shimbun on Monday.
Johnson & Johnson wholly owned firm Conor Medsystems LLCsaid, said on Monday that it will end clinical trials of its CoStar drug coated stent after it failed to meet its primary goal.
Shares of biotechnology firm Amgen, Inc. (Nasdaq: AMGN) shot up 4 percent Thursday, after results of a study for its Aranesp anemia drug for patients with small-cell lung cancer yielded no difference in survival rates than for patients who did not use the drug.
The Supreme Court upheld the nationwide ban on a controversial abortion procedure Wednesday, handing abortion opponents the long-awaited victory they expected from a more conservative bench.
Biotechnology firm Cell Genesys Inc. (Nasdaq: CEGE) shares rose sharply Tuesday, after the company said its prostate cancer drug therapy showed better-than-expected results in a clinical trial.
Shares of drug maker Cephalon (NASDAQ: Cephalon) jumped in Monday trading as a Wall Street Brokerage Firm raised the rating of the stock on Monday despite a delay in approval for a new drug.
Shares of biotechnology firm Novavax (Nasdaq: NVAX) leaped in morning trading following an announcement that its vaccine against avian flu seems effective in small animals.
